Beschreibung:
<jats:title>Abstract</jats:title><jats:p>The endocannabinoid system shows promise as a novel target for treating
psychiatric conditions. Cannabidiol (CBD), a naturally occurring cannabinoid,
has been investigated in several psychiatric conditions, with diverse effects
and an excellent safety profile compared to standard treatments. Even though the
body of evidence from randomised clinical trials is growing, it remains
relatively limited in most indications. This review comprises a comprehensive
literature search to identify clinical studies on the effects of CBD in
psychiatric conditions. The literature search included case studies, case
reports, observational studies, and RCTs published in English before July 27,
2023, excluding studies involving nabiximols or cannabis extracts containing CBD
and ∆9-tetrahydrocannabinol. Completed studies were
considered, and all authors independently assessed relevant publications.</jats:p><jats:p>Of the 150 articles identified, 54 publications were included, covering the
effects of CBD on healthy subjects and various psychiatric conditions, such as
schizophrenia, substance use disorders (SUDs), anxiety, post-traumatic stress
disorder (PTSD), and autism spectrum disorders. No clinical studies have been
published for other potential indications, such as alcohol use disorder,
borderline personality disorder, depression, dementia, and
attention-deficit/hyperactivity disorder. This critical review
highlights that CBD can potentially ameliorate certain psychiatric conditions,
including schizophrenia, SUDs, and PTSD. However, more controlled studies and
clinical trials, particularly investigating the mid- to long-term use of CBD,
are required to conclusively establish its efficacy and safety in treating these
conditions. The complex effects of CBD on neural activity patterns, likely by
impacting the endocannabinoid system, warrant further research to reveal its
therapeutic potential in psychiatry.</jats:p>